KR100650489B1 - 목시플록사신 제약 제제 - Google Patents

목시플록사신 제약 제제 Download PDF

Info

Publication number
KR100650489B1
KR100650489B1 KR1020017005833A KR20017005833A KR100650489B1 KR 100650489 B1 KR100650489 B1 KR 100650489B1 KR 1020017005833 A KR1020017005833 A KR 1020017005833A KR 20017005833 A KR20017005833 A KR 20017005833A KR 100650489 B1 KR100650489 B1 KR 100650489B1
Authority
KR
South Korea
Prior art keywords
moxifloxacin
oral administration
pharmaceutical formulation
lactose
administration according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020017005833A
Other languages
English (en)
Korean (ko)
Other versions
KR20010089424A (ko
Inventor
파트릭 보쉐
한스 프리드리히 마러
클라우스 바이제만
Original Assignee
바이엘 헬스케어 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7889824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100650489(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이엘 헬스케어 아게 filed Critical 바이엘 헬스케어 아게
Publication of KR20010089424A publication Critical patent/KR20010089424A/ko
Application granted granted Critical
Publication of KR100650489B1 publication Critical patent/KR100650489B1/ko
Assigned to 바이엘 파마 악티엔게젤샤프트 reassignment 바이엘 파마 악티엔게젤샤프트 권리의 전부이전등록 Assignors: 바이엘 헬스케어 아게
Assigned to 바이엘 인텔렉쳐 프로퍼티 게엠베하 reassignment 바이엘 인텔렉쳐 프로퍼티 게엠베하 권리의 전부이전등록 Assignors: 바이엘 파마 악티엔게젤샤프트
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020017005833A 1998-11-10 1999-10-29 목시플록사신 제약 제제 Expired - Lifetime KR100650489B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19855758 1998-11-10
DE19855758.2 1998-11-10

Publications (2)

Publication Number Publication Date
KR20010089424A KR20010089424A (ko) 2001-10-06
KR100650489B1 true KR100650489B1 (ko) 2006-11-28

Family

ID=7889824

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020017005833A Expired - Lifetime KR100650489B1 (ko) 1998-11-10 1999-10-29 목시플록사신 제약 제제

Country Status (41)

Country Link
US (1) US6610327B1 (https=)
EP (1) EP1128831B1 (https=)
JP (1) JP4809978B2 (https=)
KR (1) KR100650489B1 (https=)
CN (1) CN1149993C (https=)
AR (1) AR021074A1 (https=)
AT (1) ATE279193T1 (https=)
AU (1) AU745282B2 (https=)
BG (1) BG64974B1 (https=)
BR (2) BR9915208A (https=)
CA (1) CA2349161C (https=)
CO (1) CO5070571A1 (https=)
CU (1) CU23260B7 (https=)
CZ (1) CZ292069B6 (https=)
DE (1) DE59910858D1 (https=)
DK (1) DK1128831T3 (https=)
EE (1) EE04418B1 (https=)
ES (1) ES2229786T3 (https=)
HK (1) HK1042245B (https=)
HN (1) HN1999000183A (https=)
HR (1) HRP20010332B1 (https=)
HU (1) HU229065B1 (https=)
ID (1) ID29089A (https=)
IL (2) IL142642A0 (https=)
MA (1) MA26757A1 (https=)
MY (1) MY121114A (https=)
NO (1) NO319342B1 (https=)
NZ (1) NZ511554A (https=)
PE (1) PE20001304A1 (https=)
PL (1) PL194020B1 (https=)
PT (1) PT1128831E (https=)
RU (1) RU2230555C9 (https=)
SI (1) SI1128831T1 (https=)
SK (1) SK283936B6 (https=)
SV (1) SV1999000194A (https=)
TR (1) TR200101310T2 (https=)
TW (1) TW580388B (https=)
UA (1) UA72483C2 (https=)
UY (1) UY25792A1 (https=)
WO (1) WO2000027398A1 (https=)
ZA (1) ZA200103141B (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
EP1663226A1 (en) * 2003-09-03 2006-06-07 Ranbaxy Laboratories Limited Pharmaceutical compositions of moxifloxacin and processes for their preparation
CN1330306C (zh) * 2004-08-11 2007-08-08 深圳市天一时科技开发有限公司 莫西沙星明胶胶囊剂及其制备方法
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
CN100363001C (zh) * 2005-09-21 2008-01-23 深圳市天一时科技开发有限公司 一种莫西沙星胶囊剂及其制备方法
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
PT2349220E (pt) * 2008-10-09 2012-10-11 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Utilização de solventes orgânicos na granulação húmida de moxifloxacina
WO2010066385A1 (de) 2008-12-08 2010-06-17 Ratiopharm Gmbh Kompaktiertes moxifloxacin
TR200907227A2 (tr) * 2009-09-18 2011-04-21 Bi̇lgi̇ç Mahmut Çözünürlüğü yüksek stabil mikronize granüller.
CN101890169B (zh) * 2009-11-16 2013-09-11 江苏亚邦强生药业有限公司 莫西沙星口服制剂及其制备方法
WO2011086577A2 (en) * 2010-01-12 2011-07-21 Msn Laboratories Limited Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts
CN102247313A (zh) * 2010-06-11 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服缓释固体制剂
CN102247314A (zh) * 2011-01-12 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服固体制剂
EP2510929A1 (en) * 2011-04-11 2012-10-17 Innocoll Technologies Limited Methods for treating bacterial infection
MX2011004759A (es) 2011-05-04 2012-11-21 Senosiain S A De C V Lab Nuevas formas solidas de antibioticos.
RU2466718C1 (ru) * 2011-10-14 2012-11-20 Закрытое акционерное общество "Брынцалов-А" Фармацевтический препарат моксифлоксацина
US9358261B2 (en) 2011-10-25 2016-06-07 U.S. Phytotherapy, Inc. Additional artemisinin and berberine compositions and methods of making
WO2013063271A1 (en) * 2011-10-25 2013-05-02 U.S. Phytotherapy, Inc. Artemisinin and berberine compositions and methods of making
EP2770985A4 (en) 2011-10-25 2015-01-21 U S Phytotherapy Inc ARTEMISININE AND BERBERINE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US9675582B2 (en) 2011-10-25 2017-06-13 U.S. Phytotherapy, Inc. Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the Zika virus
BR112014012994A2 (pt) * 2011-11-30 2017-06-13 Toyama Chemical Co Ltd tablete contendo hidrato de metanossulfonato do ácido 1-ciclopropil-8-(difluorometóxi)-7-[(1r)-1-metil-2,3-diidro-1h-isoindol-5-il]-4-oxo-1, 4-diidroquinolina-3-carboxílico
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
CN102525982A (zh) * 2012-02-21 2012-07-04 天津市汉康医药生物技术有限公司 一种稳定的盐酸莫西沙星药物组合物
CN102600093B (zh) * 2012-04-11 2013-06-05 南京优科生物医药有限公司 一种莫西沙星片剂及其制备方法
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN103768063B (zh) * 2012-10-19 2016-04-20 深圳信立泰药业股份有限公司 一种盐酸莫西沙星药物组合物及其制备方法
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
WO2015093669A1 (ko) * 2013-12-20 2015-06-25 씨제이헬스케어 주식회사 목시플록사신 수성 제형 및 이의 제조방법
RU2558932C1 (ru) * 2014-05-22 2015-08-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция моксифлоксацина и способ ее приготовления

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601566A1 (de) * 1986-01-21 1987-07-23 Bayer Ag Pharmazeutische zubereitungen von ciprofloxacin
US5286754A (en) 1986-01-21 1994-02-15 Bayer Aktiengesellschaft Pharmaceutical formulations of ciprofloxacin
WO1989003681A1 (en) * 1987-10-19 1989-05-05 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma
JPH01175936A (ja) * 1987-12-28 1989-07-12 Kyorin Pharmaceut Co Ltd ６．８−ジフルオロ−１−（２−フルオロエチル）−１，４−ジヒドロ−７−（４−メチル−１−ピペラジニル）−４−オキソ−３−キノリンカルボン酸を有効成分とする錠剤
DE3906365A1 (de) 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
EP0449445A3 (en) * 1990-03-27 1993-08-25 Pfizer Inc. Preparation of beta-ketoesters useful in preparing quinolone antibiotics
TW209865B (https=) * 1992-01-10 1993-07-21 Bayer Ag
DE19546249A1 (de) * 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
PA8466701A1 (es) * 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino

Also Published As

Publication number Publication date
HK1042245B (zh) 2005-03-11
HU229065B1 (en) 2013-07-29
HRP20010332B1 (hr) 2011-01-31
SK6102001A3 (en) 2001-12-03
CO5070571A1 (es) 2001-08-28
EP1128831B1 (de) 2004-10-13
ATE279193T1 (de) 2004-10-15
CN1149993C (zh) 2004-05-19
UY25792A1 (es) 2001-08-27
PT1128831E (pt) 2005-01-31
SI1128831T1 (en) 2005-04-30
PE20001304A1 (es) 2000-12-30
HUP0104762A3 (en) 2002-10-28
NZ511554A (en) 2003-07-25
ID29089A (id) 2001-07-26
KR20010089424A (ko) 2001-10-06
WO2000027398A1 (de) 2000-05-18
MA26757A1 (fr) 2004-12-20
CN1325306A (zh) 2001-12-05
ZA200103141B (en) 2002-05-07
TW580388B (en) 2004-03-21
HRP20010332A2 (en) 2002-06-30
AR021074A1 (es) 2002-06-12
US6610327B1 (en) 2003-08-26
SV1999000194A (es) 2000-10-16
AU745282B2 (en) 2002-03-21
CZ20011652A3 (cs) 2001-08-15
BG105459A (en) 2001-12-29
DK1128831T3 (da) 2005-01-17
UA72483C2 (en) 2005-03-15
HK1042245A1 (en) 2002-08-09
IL142642A0 (en) 2002-03-10
DE59910858D1 (de) 2004-11-18
CA2349161C (en) 2008-01-29
BG64974B1 (bg) 2006-11-30
CZ292069B6 (cs) 2003-07-16
JP2002529415A (ja) 2002-09-10
BRPI9915208A (pt) 2001-07-31
HUP0104762A2 (hu) 2002-05-29
ES2229786T3 (es) 2005-04-16
HN1999000183A (es) 1999-11-01
BRPI9915208B1 (pt) 2011-11-01
AU1267400A (en) 2000-05-29
MY121114A (en) 2005-12-30
NO20012248D0 (no) 2001-05-07
CA2349161A1 (en) 2000-05-18
RU2230555C2 (ru) 2004-06-20
SK283936B6 (sk) 2004-05-04
RU2230555C9 (ru) 2006-02-27
BRPI9915208B8 (pt) 2021-07-06
IL142642A (en) 2006-10-05
EE200100259A (et) 2002-12-16
BR9915208A (pt) 2001-07-31
NO20012248L (no) 2001-06-06
EP1128831A1 (de) 2001-09-05
NO319342B1 (no) 2005-07-18
EE04418B1 (et) 2005-02-15
PL194020B1 (pl) 2007-04-30
CU23260B7 (es) 2008-01-24
TR200101310T2 (tr) 2001-10-22
JP4809978B2 (ja) 2011-11-09
PL348112A1 (en) 2002-05-06

Similar Documents

Publication Publication Date Title
KR100650489B1 (ko) 목시플록사신 제약 제제
US5731000A (en) Stabilized pharmaceutical composition containing bupropion
CA2338256C (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
CZ268197A3 (cs) Farmaceutická kompozice stabilizovaná zásaditým činidlem
US4639458A (en) Tablet and formulation
SK282594B6 (sk) Spôsob prípravy tabletkového prípravku
US20070104785A1 (en) Tablets of linezolid form iii and processes for their preparation
CA2764172A1 (en) A thrombin receptor antagonist and clopidogrel fixed dose tablet
WO2006134610A1 (en) Efavirenz pharmaceutical composition having enhanced dissolution profile
JP3573287B2 (ja) 高吸収性固形製剤
SK2132002A3 (en) Ciprofloxacin containing pharmaceutical composition and process for the preparation thereof
US20030229101A1 (en) Tablets comprising ciprofloxacin hydrochloride
WO2011086577A2 (en) Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts
JP2003231637A (ja) 固形製剤
AU2025234265A1 (en) A pharmaceutical oral dosage form of Q203
EP1895990A2 (en) Formulations containing pantoprazole free acid and its salts
HRP20020153A2 (en) Ciprofloxacin containing pharmaceutical composition and process for the preparation thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20010509

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20040902

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20040903

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060102

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20061030

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20061121

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20061122

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
G170 Re-publication after modification of scope of protection [patent]
PG1701 Publication of correction
PR1001 Payment of annual fee

Payment date: 20091110

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20101118

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20111028

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20121114

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20121114

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20131031

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20131031

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20151030

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20151030

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20161028

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20161028

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20171027

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20171027

Start annual number: 12

End annual number: 12

PC1801 Expiration of term

Termination date: 20200429

Termination category: Expiration of duration